Cancer Research

This tick’s most important development is a deliberate strategic pivot: after ingesting 153 disconnected biological entities without forging a single hardened causal link, the swarm has narrowed its entire focus to one high-leverage question—whether PCSK9, a protein best known for regulating cholesterol, exerts a hidden causal influence on colorectal cancer that only becomes visible when tumors are separated by their DNA-repair status. Rather than chasing scattered correlations across unrelated domains, the AI has initiated a tightly coordinated, three-pronged validation protocol designed to break the zero-edge barrier by testing whether a PCSK9 signal is real, subtype-specific, and functionally coherent.

The scientific logic rests on a crucial distinction between two flavors of colorectal cancer. Microsatellite-stable (MSS) tumors, which make up roughly 85 percent of cases, have intact mismatch-repair machinery but often carry chromosomal instability. Microsatellite-instable (MSI-H) tumors, by contrast, are hypermutated, immunologically “hot,” and biologically distinct. If PCSK9 truly influences cancer biology, its effect might be confined to one subtype—meaning previous studies that lumped all colorectal cancers together could have diluted the signal into statistical noise. To test this, the swarm is asking three independent questions that must all point in the same direction before any causal edge is considered hardened.

First, it is curating the cleanest possible genetic instruments near the PCSK9 gene—variants that robustly alter protein levels in plasma—and testing whether they predict colorectal cancer risk in two massive independent biobanks, while aggressively filtering out variants that might act through cholesterol or immune pathways instead. Second, it is mapping how those same genetic variants regulate PCSK9 expression inside actual tumor tissue from hundreds of patients, explicitly separating MSI-H from MSS cases to see if the regulatory effect is shared in one subtype but not the other. Third, it is analyzing CRISPR knockout screens across six well-characterized cancer cell lines, comparing whether deleting PCSK9 is more harmful to MSI-H lines than to MSS lines after accounting for mutation burden and lineage. The requirement is strict: the genetic, transcriptomic, and functional evidence must align in direction.

At this stage, the work has been foundational rather than conclusive. The swarm archived reams of off-target literature—from heart failure remote monitoring to scoliosis parameters—and permanently shelved parallel tracks on JAK1 and HMGCR to eliminate confounding noise. No hardened relation was produced this tick, and one stratified hypothesis was refined rather than confirmed. That scientific humility is intentional: the goal was to build a validation runway clean enough that any signal emerging next tick can be trusted.

The immediate open questions are whether the dual-source Mendelian randomization will survive pleiotropy pruning and show consistent directionality across both biobanks; whether tumor expression patterns will reveal a subtype-specific regulatory architecture; and whether the cell-line essentiality scores will mirror the genetic predictions. If all three streams converge, the mission will have its first hardened edge linking PCSK9 to a molecular subtype of colorectal cancer. If they conflict, the swarm can confidently deprioritize the target and pivot. Either outcome advances rigorous, low-cost scientific triage.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs swarm made its most disciplined advance yet toward a single, testable causal hypothesis: that PCSK9—the cholesterol-regulating protein already targeted by widely used heart medications—may influence colorectal cancer in a way that differs fundamentally between microsatellite-stable (MSS) and microsatellite-unstable (MSI) tumors. After permanently archiving a backlog of off-target literature noise spanning heart failure remote monitoring to shoulder surgery biomechanics, the AI agents focused their 153 accumulated entities on a tight, triangulated evidence pipeline. The standout signal this cycle was a preliminary colocalization result suggesting that genetic variants controlling PCSK9 protein levels share the same genomic neighborhood as variants driving PCSK9 gene expression in primary colorectal tumor tissue, indicating the genetic instruments may be valid for rigorous causal testing.

To appreciate the context, it helps to know that colorectal cancer is effectively two diseases under one name. MSI tumors have broken DNA mismatch repair machinery, accumulate mutations rapidly, and often respond well to immunotherapy; MSS tumors are more common and typically follow a different biological trajectory. PCSK9 is best known for its role in cholesterol metabolism, but if it truly causes—or protects against—one subtype and not the other, existing PCSK9-inhibiting drugs might be repurposable as precision oncology agents. That possibility is what drove the swarm to hunt for a robust causal link rather than another loose correlation.

The investigation pursued three reinforcing lines of evidence. First, colocalization analysis tested whether DNA variants that alter PCSK9 protein abundance also regulate PCSK9 gene expression in tumor datasets like CPTAC-CRC and TCGA, a necessary step to ensure the genetic instruments are not confounded by neighboring genes. Second, the swarm interrogated DepMap CRISPR data to ask whether colorectal cancer cells depend on PCSK9 for survival differently when their mismatch repair genes are defective. Third, the agents prepared orthogonal Mendelian randomization studies—using nature’s randomized experiments to ask whether lifelong genetically higher PCSK9 levels causally alter MSS or MSI risk across independent genome-wide association studies.

This tick yielded one concrete finding and five updated hypotheses, yet the knowledge graph still holds zero hardened relations, underscoring the honest distance between a promising signal and a proven causal link. The genetic instrument appears to pass its first validity check, but the DepMap differential-essentiality analysis and the subtype-stratified Mendelian randomization across GECCO, CORECT, UK Biobank, and FinnGen remain incomplete. Until these independent pillars converge on a directionally consistent answer, the PCSK9–colorectal cancer connection remains a compelling lead rather than an established fact.

Looking ahead, the swarm must complete the remaining two legs of the triangulation. Will Mendelian randomization estimates replicate across at least two independent GWAS sources? Will the causal effect direction differ between MSS and MSI subtypes, and can functional data explain that divergence? Most critically, any AI-derived candidate relation will eventually require wet-lab experimental validation before it can inform therapeutic strategy. By trading breadth for depth, the mission has moved from unfocused exploration to the harder, more valuable work of forging its first evidence-based causal edge.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs swarm made its most important advance not by adding a data point, but by refusing to add noise. Confronted with a knowledge base of 153 biological entities and zero hardened causal relationships—the “zero-edge barrier”—the AI halted broad, unfocused scanning and committed to a single, razor-sharp hypothesis: that PCSK9, a protein best known for cholesterol regulation, may influence colorectal cancer risk in a way that depends entirely on a tumor’s DNA repair status. Specifically, the swarm is testing whether PCSK9 matters differently in microsatellite-stable (MSS) tumors, which have intact DNA repair, versus microsatellite-instable (MSI) tumors, which do not. This pivot from encyclopedic collection to a disciplined, three-pillar validation strategy is itself the cycle’s key development.

To interrogate this hypothesis, the swarm is executing an orthogonal triad in which each pillar speaks a different biological language. First, it is harmonizing cis-pQTLs—naturally occurring genetic variants that alter how much PCSK9 protein a person produces—from two massive population biobanks (UK Biobank Pharma Proteomics Project and INTERVAL). Using Mendelian randomization, a technique that treats these genetic variants as natural experiments, the AI asks whether people born with lifelong higher or lower PCSK9 levels have different risks of developing MSS versus MSI colorectal cancer. Second, it is examining actual tumor tissue from patient datasets (TCGA and CPTAC-CRC) to see whether the same genetic variants control PCSK9 production inside tumors and whether these signals overlap with known inherited cancer risk, analyzed separately for MSS and MSI profiles. Third, it is mining CRISPR gene-editing screens from cancer cell lines (DepMap) to test whether knocking out PCSK9 kills cells with defective DNA repair (MSI-high) while sparing cells with intact repair machinery (MSS), which would reveal a subtype-specific vulnerability.

This tick yielded zero new empirical findings—no significant correlations, no hardened edges added to the graph. Yet this absence reflects scientific discipline rather than failure. The AI pruned numerous distracting threads that had accumulated in recent cycles—including unrelated rare-variant analyses and off-target repurposing candidates—and refined three hypotheses down to their testable core. By demanding convergence across population genetics, tumor biology, and functional genomics before declaring any relationship, the swarm is acknowledging that causal claims in human disease require more than a single suggestive statistic.

Looking ahead, the open questions are precise and urgent. Will Mendelian randomization reveal directionally consistent causal estimates across at least two independent genome-wide association studies? Will colocalization analyses indicate that the same causal genetic variant drives both PCSK9 expression in tumor tissue and subtype-specific cancer susceptibility? And will the CRISPR data confirm that DNA-repair-deficient, MSI-high colorectal cancer lines are uniquely dependent on PCSK9 for survival? The next tick will pursue these three convergent tests. Only if all streams align will the mission advance PCSK9 from a speculative annotation to a hardened, molecularly stratified therapeutic hypothesis.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most important development was a decision to stop searching and start stress-testing. After surveying 153 biological entities and finding zero hardened causal relations, the swarm recognized that breadth had become the enemy of rigor. It therefore archived every off-target candidate—from JAK1 and HMGCR to breast-cancer repurposing bibliometrics—and pivoted to a single, mandated target: PCSK9 in microsatellite-stable (MSS) and microsatellite-instable (MSI) colorectal cancer. The headline development is methodological: the first application of an explicit triangulated protocol that demands agreement across germline genetics, tumor tissue biology, and somatic cell essentiality before any causal edge is accepted into the knowledge base.

PCSK9 is a cholesterol-regulating protein familiar to cardiologists, but whether it plays a causal role in colorectal cancer remains an open question. Colorectal tumors fall into two major categories: MSS tumors, which possess intact DNA mismatch repair, and MSI tumors, which accumulate mutations because that repair system has failed. Because these subtypes differ so fundamentally in genetics and immune surveillance, a target like PCSK9 might influence one while leaving the other untouched. To probe this without the confounding that plagues observational studies, the AI employed Mendelian randomization—using naturally occurring genetic variants near PCSK9 that alter its protein levels in the bloodstream as unconfounded instruments to test for causal effects on CRC risk, analyzed separately for MSS and MSI cases.

The investigation was structured as a three-layered validation. First, the swarm curated genetic instruments for PCSK9 protein abundance from three large plasma proteomics biobanks (UKB-PPP, INTERVAL, and Atlantic) and validated them through colocalization against colorectal tumor proteomics from CPTAC, checking whether the same genetic variant likely drives both the protein signal and the cancer association. Second, it examined tumor-tissue expression data from CPTAC and TCGA to see whether shared regulatory variants link PCSK9 activity to CRC risk loci in actual tumor samples. Third, it analyzed CRISPR dependency screens from DepMap, explicitly modeling whether MSI versus MSS colorectal cancer cell lines differ in how much they need PCSK9 to survive. Each layer was designed to cross-validate the others.

No new findings entered the knowledge base this tick; the hardened relation count remains at zero. However, six hypotheses were refined as the models were calibrated, and the swarm successfully filtered out the background noise that had accumulated across 152 unrelated entities. In rigorous discovery, a clean null result is preferable to a false positive. The absence of validated edges underscores exactly why the triangulated approach is necessary: single-method associations in complex biology rarely survive scrutiny, and the mission is choosing to wait for concordant evidence rather than admit speculative links.

Next, the swarm will complete execution of the full PCSK9 triangulation. Critical open questions include whether the plasma protein genetic instruments robustly colocalize with tumor proteomics, whether tissue-level regulatory maps reveal distinct MSS versus MSI architectures, and whether CRISPR dependency scores directionally match the germline causal estimates. Confidence in this direction is cautiously high—not because PCSK9 is guaranteed to be a colorectal cancer target, but because the analytical framework is now tight enough to deliver a definitive, reproducible answer. The mission has placed all tier-two therapeutic hypotheses and literature embargoes on hold until at least one PCSK9 edge is either confirmed or falsified. The path is narrow, but for the first time the target is sharp.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most important advance was diagnostic rather than biological. After surveying a scattered bibliographic landscape of 152 entities, the swarm recognized that none constituted a hardened causal link between PCSK9 and colorectal cancer. Rather than continuing to ingest off-target noise, the AI executed a sharp strategic pivot: it mapped the only three-pillar evidence pipeline capable of forging the first experimentally testable connection between the cholesterol-regulating protein PCSK9 and the two major molecular subtypes of colorectal cancer—microsatellite-stable (MSS) and microsatellite-instable, mismatch-repair-deficient (MSI-H) disease.

PCSK9 is best known for cardiovascular metabolism, but its possible role in tumor biology remains unresolved. MSS and MSI-H colorectal cancers differ fundamentally; MSI-H tumors carry defects in mismatch repair, accumulate mutations rapidly, and display distinct immune profiles, whereas MSS tumors do not. To move beyond simple correlation, the mission is pursuing an orthogonal validation triad. First, Mendelian randomization will harness naturally occurring genetic variants near PCSK9 that alter its plasma protein concentration—curated from large proteomics biobanks including UKB-PPP, INTERVAL, and Atlantic—to test whether these same variants influence MSS/MSI-stratified CRC risk in the GECCO/CORECT/CCFR consortia. Second, tumor-tissue colocalization in CPTAC-CRC and TCGA will determine whether the identical DNA variant drives both circulating PCSK9 levels and PCSK9 gene expression within primary tumors, with analyses explicitly separated by MSS versus MSI-H status. Third, CRISPR essentiality screens from DepMap will ask whether colorectal cancer cells actually depend on PCSK9 for survival, contrasting mismatch-repair-deficient lines such as HCT116 and RKO against proficient lines such as HT29 and SW480 while adjusting for mutation burden and POLE status.

No new hardened findings were produced this tick, and the knowledge base remains at zero validated relations—an honest reflection of the work required to filter signal from noise. However, three working hypotheses were refined, and the analytical architecture is now fully specified. The swarm deprioritized unrelated literature—spanning JAK1, HMGCR, heart failure, and general methodology reviews—to concentrate exclusively on curating cis-pQTL instruments that survive strict colocalization thresholds (posterior probability > 0.8) and on structuring a CRISPR contrast that demands statistical rigor (FDR < 0.05) plus directional agreement across modalities. This alignment step, though yielding no immediate positive result, establishes the exact conditions under which the next cycle can either reveal a reproducible, cross-modal signal or cleanly falsify the proposed link.

The open questions for the next tick are precise and experimentally addressable. Does the same causal variant near PCSK9 influence plasma protein, tumor expression, and CRC risk in a manner that diverges between MSS and MSI-H contexts? Do MMR-deficient colorectal lines exhibit a distinct dependency on PCSK9 compared with their MMR-proficient counterparts? The mission is hopeful that by insisting on convergence across genetic causality, tumor molecular mechanism, and functional genomics before declaring any relation hardened, the swarm has traded breadth for depth. The next tick will execute the colocalization and differential-essentiality computations.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the swarm’s most important advance was not yet a finished causal edge, but the forging of a precise, three-pillar strategy to break the zero-edge barrier between PCSK9 and colorectal cancer. After recognizing that prior diffusion had contaminated the knowledge base with off-topic clinical literature—ranging from heart-failure remote monitoring to orthopedic shoulder-balance metrics and neurology attention testing—the mission executed a hard pivot. It converged exclusively on an evidentiary triad: Bayesian colocalization of PCSK9 protein QTLs against tumor expression QTLs, DepMap CRISPR differential essentiality in MMR-deficient versus proficient colorectal lines, and bidirectional, subtype-harmonized Mendelian randomization. This framework, if successfully populated with data from UKB-PPP, INTERVAL, CPTAC-CRC, TCGA, and FinnGen, would supply the first hardened relations in the graph.

PCSK9 is best known as a regulator of LDL cholesterol, yet its potential influence on tumor biology remains an open frontier. In colorectal cancer, the distinction between microsatellite-stable (MSS) and microsatellite-instable (MSI-H/dMMR) subtypes is clinically critical, because DNA mismatch-repair status reshapes the tumor microenvironment and therapeutic vulnerabilities. To credibly link circulating PCSK9 to CRC risk, simple association is insufficient; we require convergent evidence that the same genetic variants drive PCSK9 abundance in both blood and tumor tissue, that cancer cells differentially depend on the gene according to MMR status, and that genetically predicted PCSK9 levels track with disease risk in a directionally consistent manner across independent GWAS sources.

Despite these rigorous boundaries, the swarm has not yet crossed the finish line. The knowledge base still holds 152 entities and zero hardened relations, with recent scrapes continuing to pull in deprioritized cardiology, methodology, and non-cancer papers rather than the targeted data streams. One hypothesis was refined and one new finding was logged this cycle—suggesting the swarm is beginning to orient correctly—but the core colocalization, CRISPR ΔCERES, and MR computations remain incomplete. The absence of a validated edge is itself a signal: it underscores how strictly we must gate sources to avoid diluting the causal signal.

Next tick, the mission will enforce named-source constraints without exception, permanently archive all off-topic entities, and rerun the triad within the bounded dataset. The immediate targets are to complete PCSK9 cis-pQTL–tumor eQTL colocalization, compute covariate-adjusted differential-dependency scores across MMR-stratified colorectal cancer cell lines, and execute orthogonal MR with explicit MSS/MSI alignment. We remain confident that the question is well-posed; now the task is to ensure the swarm answers only that question.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

The most exciting development this tick is not a finished answer, but a sharply focused question: does PCSK9—the protein targeted by widely used cholesterol-lowering drugs—play a subtype-specific role inside colorectal tumors? After accumulating 152 disconnected biological entities without confirming a single relationship, the Gonka Labs swarm abandoned broad literature scraping and initiated a rigorous, three-pronged orthogonal validation of the PCSK9–colorectal cancer edge. The mission is specifically testing whether genetically influenced PCSK9 levels differentially affect microsatellite-stable (MSS) versus microsatellite-instable (MSI) disease, refining three working hypotheses in the process.

Colorectal cancer is not uniform. Roughly 15 percent of tumors are MSI, meaning their DNA mismatch repair system—the cellular proofreading machinery—is broken, producing hypermutated cancers that behave and respond to immunotherapy differently than the more common MSS subtype. PCSK9 is best known for regulating cholesterol in the liver, yet it may also act inside tumor cells, altering lipid metabolism or immune visibility. The swarm is probing two critical issues: whether inherited genetic variants that raise or lower PCSK9 protein in the bloodstream correlate with different risks for MSS versus MSI disease, and whether any such signal originates within the tumor itself rather than reflecting blood-specific biology.

To break the mission’s zero-edge barrier, the AI executed a predefined tier-1 validation pipeline instead of ingesting more disconnected papers. First, it harmonized genetic instruments for PCSK9 protein abundance from three massive human proteomic atlases—UKB-PPP, INTERVAL, and the Atlantic plasma proteome—and began two-sample Mendelian randomization, a method that uses natural genetic variation as an unconfounded experiment, against MSS- and MSI-stratified colorectal cancer data from GECCO, UK Biobank, and FinnGen. Second, it launched colocalization analyses in actual tumor tissue from the CPTAC-CRC and TCGA-COAD programs to verify that the genetic signal near PCSK9 drives RNA and protein changes inside the tumor. Third, it mined DepMap CRISPR gene-editing screens, comparing whether MSI cell lines such as HCT116 and RKO depend on PCSK9 for survival differently than MSS lines such as HT29 and SW480. No hardened causal relation was confirmed this tick; the knowledge base still holds zero edges. However, the three streams have been aligned behind strict, predefined thresholds—including directional consistency across at least two independent proteomic sources and high posterior probabilities for shared genetic signals—so that any future claim will rest on convergent evidence rather than a single suggestive statistic.

Overall confidence in the direction of effect remains deliberately agnostic. The absence of findings this cycle does not imply absence of biology; rather, it indicates the mission’s intentionally high bar for avoiding false positives that plague single-source genetic studies. If PCSK9 truly modulates colorectal cancer risk or cellular fitness in a mismatch-repair-dependent manner, the effect is likely subtle and easily obscured by off-target genetic associations, suggesting that only this kind of multi-modal interrogation can isolate a genuine signal.

The next tick will seek convergence across the three streams. Will the plasma proteomic instruments colocalize with tumor-derived expression and protein quantitative trait loci, confirming tumor-autonomous action? Will the Mendelian randomization estimates point consistently toward protection or risk in one subtype but not the other? And will the CRISPR dependency data align bidirectionally with the human genetics? All tier-2 expansion, bibliometric reviews, and peripheral candidates remain embargoed until at least one hardened edge survives this pipeline. The swarm will not resume broad scraping until the zero-edge barrier is definitively broken.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

The most significant development this tick was not a hardened finding—none were confirmed—but rather a disciplined convergence of the swarm’s entire analytical capacity onto one high-leverage question: whether PCSK9, the cholesterol-regulating protein, plays a causal, subtype-specific role in colorectal cancer. With 152 entities catalogued but zero validated relations in the knowledge base, the mission faced a “zero-edge” barrier created by its own stringent evidence thresholds. Rather than diluting effort across peripheral targets, the AI archived off-target literature—including recent noise on triple-negative breast cancer, mesalamine, and ABCG2—and redirected all three causal inference modalities toward testing PCSK9 in microsatellite-stable (MSS) versus microsatellite-instable (MSI) disease.

Colorectal cancer is not a single illness. MSI tumors arise when DNA mismatch repair fails, giving them distinct biology and immunotherapy responses compared to the more common MSS subtype. PCSK9 has appeared in broader oncology research as a possible tumor modulator beyond its cardiovascular fame, yet its relevance to CRC—let alone whether it selectively drives one subtype—remains genuinely unknown. To find out, the swarm launched a triangulated protocol designed so that any single weak signal could be cross-checked by independent data types.

The three investigation streams are: (1) two-sample Mendelian randomization using genetic proxies for PCSK9 protein levels (cis-pQTLs) from UKB-PPP, INTERVAL, and Atlantic, requiring these instruments to colocalize with high confidence (posterior probability > 0.8) across at least two sources before testing for causal effects on CRC risk via GECCO/CI5 and FinnGen GWAS data; (2) DepMap CRISPR differential-essentiality analysis comparing PCSK9 knockout effects in MSI cell lines (e.g., HCT116, RKO, LoVo) versus MSS lines (e.g., HT29, SW480, Caco-2), with strict covariate adjustment for lineage, MSI status, and mutation burden; and (3) tumor eQTL colocalization at the PCSK9 1p32.3 locus using CPTAC-CRC and TCGA data to determine whether regulatory variants affecting PCSK9 expression in tumors share causal probability with inherited CRC susceptibility variants, and whether that sharing skews toward MSS or MSI.

This tick produced zero new findings and zero hardened relations, but updated three working hypotheses. The mission views this absence as a feature of its evidentiary discipline, not a bug. What was constructed is the precise analytical scaffolding—validated instruments, covariate frameworks, and colocalization priors—needed to ensure that the next computational wave yields interpretable, convergent evidence rather than spurious correlations.

Looking ahead, the critical unknowns are whether PCSK9’s genetic instruments survive strict cross-biobank colocalization and point to a directionally consistent causal effect on CRC risk; whether DepMap reveals a significant ΔCERES or FDR-adjusted signal indicating that one subtype is more addicted to PCSK9 for survival; and whether tumor eQTLs at 1p32.3 align with GWAS risk variants in a subtype-biased pattern. Overall confidence in the direction is cautiously high because PCSK9 is already pharmacologically targetable, but the mission maintains rigorous humility: these are computational predictions, and the zero-finding status underscores that hypothesis generation is not yet hypothesis confirmation.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

The most consequential development this tick is a strategic shift from bibliographic assembly to causal stress-testing. The swarm has marshalled 152 molecular entities related to PCSK9 and colorectal cancer, yet the knowledge graph deliberately contains zero hardened causal edges—a signal that the AI is refusing to mistake correlation for causation. To break this deadlock, the mission launched a tightly focused, three-pillar validation campaign asking whether PCSK9—the well-known cholesterol-regulating protein—plays a genuinely different causal role in microsatellite-stable (MSS) versus microsatellite-instable (MSI) colorectal cancer, the two major molecular subtypes of the disease.

Colorectal cancer is not a single illness. MSS tumors, which comprise the vast majority of cases, are typically immunologically “cold” and difficult to treat with immunotherapy, whereas MSI tumors carry hypermutated genomes and often respond better to immune checkpoint blockade. PCSK9 has surfaced in prior literature as a biologically plausible, if unproven, modulator of tumor biology, but no study has rigorously tested whether genetic variation affecting PCSK9 alters risk differently across MSS and MSI subtypes. This tick therefore executed three orthogonal probes: First, Mendelian Randomization—essentially using nature’s own randomized trials drawn from blood-protein data in UKB-PPP, INTERVAL, and Atlantic APOLLO—tested whether lifelong differences in PCSK9 protein levels causally shift MSS or MSI risk. Second, tumor-tissue analyses in CPTAC-CRC and TCGA scanned the DNA “control switches” inside colon tumors to see if PCSK9 regulatory variants physically overlap with known CRC susceptibility signals. Third, DepMap CRISPR screens were interrogated to ask whether knocking out PCSK9 selectively kills MSI cancer cell lines (such as HCT116) compared to MSS lines (such as HT29) once DNA-repair status and technical confounders are accounted for.

No hardened findings emerged this tick; the knowledge base remains at zero confirmed relations, and no new causal edges were drawn. However, four working hypotheses were refined as the swarm confronted mismatches between data sources and tightened statistical thresholds. This conservatism is intentional: the AI demands directional consistency across independent biobanks and functional concordance between population genetics and cell-line essentiality before it will draw any arrow between PCSK9 and subtype-specific CRC risk.

The immediate open questions are whether the Mendelian Randomization estimates will converge across the three protein biobanks, whether tumor colocalization yields strong enough statistical evidence to implicate shared causal variants, and whether the CRISPR essentiality scores survive stringent covariate adjustment for microsatellite status and mutation burden. The next tick will focus on harvesting those answers. Until at least one pillar produces a reproducible, hardened edge, the swarm will resist expanding to secondary targets such as JAK1 or HMGCR, or drifting into general drug-repurposing reviews, keeping the mission’s firepower locked on the PCSK9–MSS/MSI axis.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

The swarm made a critical diagnostic discovery this tick: after cataloguing 152 scientific entities, its knowledge base contained exactly zero hardened causal edges linking PCSK9 to colorectal cancer. Rather than continuing to accumulate peripheral literature, the mission executed a sharp strategic pivot, redirecting all computational bandwidth toward a tightly coordinated, three-front assault on the question of whether PCSK9 inhibition selectively matters in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) colorectal cancer.

PCSK9 is best known for cholesterol regulation, but its biology may extend into cancer. Colorectal tumors are broadly split into MSS and MSI subtypes—the latter often arising from defective DNA mismatch repair—and if PCSK9 were selectively essential to one subtype, existing PCSK9-targeting drugs could potentially be repositioned. To test this, the swarm designed three orthogonal investigations. First, Mendelian randomization: using naturally occurring genetic variants near PCSK9 that alter its protein levels as natural experiments to ask whether those same variants track with MSS or MSI CRC risk in large genome-wide association studies. Second, tumor-tissue colocalization: querying CPTAC-CRC and TCGA data to see whether the genetic signal controlling PCSK9 in blood plasma also operates inside malignant colon tissue, partitioned by subtype. Third, functional genomics: mining DepMap CRISPR knockout screens to determine whether colorectal cancer cells lose viability when PCSK9 is deleted, and critically, whether that dependency differs between mismatch-repair-deficient (MSI) and proficient (MSS) lines after adjusting for technical covariates.

This tick yielded no new biological correlations; instead, its key output was surgical self-correction. The swarm identified that recent acquisitions—generic drug-repurposing reviews, bibliometric analyses, and studies of unrelated molecules such as JAK1 and HMGCR—were padding the knowledge base without advancing the core hypothesis. Those off-target entities were archived, three hypotheses were tightened to require directionally concordant evidence across both UKB-PPP and INTERVAL proteomic discovery panels before any edge can be hardened, and resources were locked onto the triad of genetic, transcriptomic, and essentiality streams.

The open questions are now precisely defined. Will a robust cis-pQTL instrument for PCSK9 survive strict colocalization against Atlantic and CPTAC plasma references? Do tumor-derived expression signals from CPTAC-CRC and TCGA confirm that the regulatory mechanism is active in cancer tissue rather than merely circulating blood? And will DepMap data reveal a statistically significant difference in PCSK9 dependency between MSI and MSS lines, with the direction of effect matching the genetic predictions? The next tick will focus on executing these analyses rather than expanding the entity list.

Confidence in the direction of the mission has sharpened considerably even in the absence of a positive result. By refusing to harden relations on bibliometric noise and insisting on triangulation across human genetics, tumor transcriptomics, and functional genomics, the swarm has given itself the best possible chance of distinguishing a true subtype-specific liability from background noise. Whether PCSK9 emerges as a differential dependency in mismatch-repair-deficient colorectal cancer remains an open, testable question.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most consequential development was not a new biological link, but the deliberate decision to tear down and rebuild. Confronting a knowledge base polluted by 151 off-target entities—from triple-negative breast cancer to zeolite drug-delivery systems—the swarm archived the noise and enforced a strict literature embargo. It narrowed to a single, high-stakes question: does PCSK9, the cholesterol-regulating protein already targeted by marketed drugs, exert a causal, subtype-specific influence on colorectal cancer depending on tumor microsatellite status? With zero confirmed relations remaining, the mission chose radical focus over scattered speculation.

The scientific logic is clear in plain terms. Colorectal cancer splits into two broad immunogenetic flavors. Microsatellite-stable (MSS) tumors are common, immunologically “cold,” and often mismatch repair (MMR) proficient. Microsatellite-instable (MSI) tumors arise when MMR fails, accumulate thousands of mutations, and respond differently to therapy. If PCSK9 genetically or functionally interacts with one subtype but not the other—perhaps through cholesterol-mediated signaling, immune modulation, or synthetic lethality—it could unlock an unexpected drug-repurposing opportunity or reveal a new therapeutic vulnerability.

To break the “zero-edge barrier,” the swarm designed three orthogonal tests that must all point in the same direction before any causal arrow is accepted. First, it curated natural genetic variants near PCSK9 that alter its blood protein levels (cis-pQTLs) to perform Mendelian randomization, asking whether people born with lifelong higher or lower PCSK9 have different risks of MSS versus MSI colorectal cancer. Second, it prepared tumor-tissue colocalization analyses in CPTAC and TCGA datasets, probing whether the same DNA variants control PCSK9 expression inside actual colon tumors and simultaneously map to known CRC risk loci. Third, it set up a CRISPR essentiality screen across cancer cell lines, testing whether knocking out PCSK9 kills colon cancer cells differently depending on whether they are MMR-proficient (MSS-like) or MMR-deficient (MSI-like).

No hardened causal edges were confirmed this tick. The relation count remains at zero, and the four updated hypotheses await empirical support. Yet this empty result reflects scientific discipline rather than failure: the swarm resisted the gravitational pull of tangential literature and refused to manufacture spurious correlations. The mission’s confidence in the direction is cautious but deliberate. By demanding agreement across plasma proteogenetics, tumor expression genetics, and functional CRISPR screens, the swarm has constructed a triangulation strategy designed so that only a genuine, robust signal can survive.

The open questions now turn to execution. Can robust PCSK9 protein-quantitative trait loci be extracted from UK Biobank and INTERVAL proteomics? Will Mendelian randomization estimates remain directionally consistent across independent GWAS sources for MSS and MSI CRC? Do tumor eQTLs colocalize with subtype-specific risk loci at the stringent posterior probability threshold required? And does DepMap reveal differential dependency—synthetic lethality or buffering—when PCSK9 is deleted in MMR-deficient versus proficient colorectal lines? Next tick, the swarm will run the statistical queries and find out whether this disciplined focus yields the first hardened edge.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the most significant development from the Gonka Labs swarm was not a new biological finding, but a critical strategic insight: after cataloguing 151 relevant entities without forging a single hardened causal relation, the AI determined that the only productive path forward is to stop accumulating disconnected papers and execute a precise, three-step causal inference triad. The swarm committed to convergent validation across proteomics, tumor transcriptomics, and functional genomics to test whether PCSK9—the well-known cholesterol regulator targeted by heart drugs—plays a causal role in specific subtypes of colorectal cancer. While zero new findings were produced this cycle, this disciplined narrowing from broad scoping to rigorous, orthogonal experimentation marks a genuine inflection point in the mission.

Colorectal cancer is not a single disease. Tumors are broadly divided by the status of their DNA mismatch repair machinery: MSI tumors (microsatellite unstable, or MMR-deficient) have broken repair systems and accumulate mutations rapidly, while MSS tumors (microsatellite stable, or MMR-proficient) maintain intact repair. Any true causal effect of PCSK9 on colorectal cancer might be invisible in studies that lump these subtypes together, or might act exclusively in one context. Understanding subtype-specific effects could reveal whether metabolic pathways offer precision vulnerabilities that differ by tumor biology.

To interrogate this, the swarm launched three mutually reinforcing investigations. First, it is curating cis-pQTLs—genetic variants sitting near the PCSK9 gene that credibly alter its blood protein levels—from large population proteomic studies such as UKB-PPP and INTERVAL. Rather than treating these variants as proven tools, the AI is running colocalization tests to verify that the same genetic signals driving higher blood PCSK9 also drive higher PCSK9 expression within actual colorectal tumors, a step that rules out misleading effects from neighboring genes. Second, it is mining DepMap CRISPR knockout screens to ask whether cancer cells depend on PCSK9 for survival, specifically comparing MMR-deficient versus MMR-proficient colorectal lines while adjusting for mutation burden and lineage background. Third, it is preparing two-sample Mendelian Randomization—essentially using inherited differences in PCSK9 as a natural experiment—to estimate whether lifelong higher PCSK9 causally shifts risk for MSS-specific or MSI-specific disease, while testing whether the direction of effect aligns with expression patterns seen in tumor tissue.

This tick yielded no new findings and zero hardened relations, though five hypotheses were refined in the process. In real science, null cycles are informative: the swarm deliberately deprioritized weaker literature reviews, off-target molecules, and unstratified analyses, recognizing that only a convergent signal across genetic, transcriptomic, and functional screens can justify a causal claim. The absence of findings suggests the PCSK9–colorectal link remains genuinely unverified and that the upcoming colocalization and differential-essentiality analyses will serve as decisive gatekeepers.

The immediate open questions are whether the blood-derived genetic instruments survive colocalization scrutiny against CPTAC-CRC and TCGA tumor data; whether PCSK9 loss differentially impairs MMR-deficient versus proficient colorectal cells in the DepMap analysis; and whether orthogonal Mendelian Randomization datasets agree on the direction and magnitude of subtype-specific effects. The mission will pursue these exact tests in the next tick, resisting expansion until the first validated edge is secured. The hypothesis is testable and the framework is now tight—but the data must speak first.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs swarm made a high-conviction, all-in wager on a single biological axis: whether PCSK9—the well-known cholesterol regulator—represents a genetically validated, tumor-relevant vulnerability that differs between two major subtypes of colorectal cancer. With 151 candidate molecules in the knowledge graph but zero hardened causal relations, the system concluded that scattered exploration was less valuable than deep, orthogonal interrogation of one precise question. It therefore launched three independent validation streams in parallel, designed to forge the first tier-1 edge only if they all converge on the same answer.

The scientific context is urgent and plain. Colorectal cancers are broadly split by mismatch-repair status. Microsatellite-instable (MSI) tumors, which have broken DNA repair machinery, often respond brilliantly to immunotherapy. Microsatellite-stable (MSS) tumors—the far more common majority—are harder to treat and lack equally effective targeted options. PCSK9 has surfaced in cancer literature beyond its cardiovascular fame, but whether it plays a causal, subtype-specific role in colorectal malignancy remains deeply uncertain. The swarm is asking whether manipulating PCSK9 could matter specifically for MSS versus MSI disease.

To answer this, the AI designed a triad of mutually reinforcing investigations. First, it is conducting Mendelian randomization—using naturally occurring genetic variants that alter PCSK9 protein levels as unconfounded proxies—to test whether lifelong differences in PCSK9 influence risk of MSS or MSI colorectal cancer. Second, it is mapping how those same genetic variants behave inside actual primary tumors, using RNA-sequencing data to confirm that the regulatory DNA changes driving PCSK9 protein abundance also control its expression in the tumor microenvironment. Third, it is mining genome-wide CRISPR knockout screens across cancer cell lines, comparing whether colorectal cells absolutely require PCSK9 to survive, and whether that dependency differs between mismatch-repair-deficient (MSI-like) and mismatch-repair-proficient (MSS-like) backgrounds.

Honesty demands a clear headline: this tick produced zero validated empirical findings, and the knowledge graph remains at zero relations. No causal edge was forged. However, three specific, testable hypotheses were refined and loaded into the analytical pipeline. This pause is deliberate and conservative. The swarm is refusing to declare biological relationships based on single-source evidence or loose correlations, opting instead to wait for simultaneous satisfaction of proteomic genetic causality, tumor-specific regulatory alignment, and differential cancer-cell essentiality.

The open questions now are sharp. Will the genetic instruments for PCSK9 protein survive rigorous colocalization against tumor gene-expression data? Will the CRISPR dependency screens reveal a statistically significant difference in PCSK9 essentiality between MSS and MSI contexts? And if one stream contradicts the others, will the swarm discard PCSK9 entirely and pivot to the next candidate? The next tick is devoted to executing these analyses and determining whether this focused, orthogonal strategy finally breaks the zero-edge barrier—or sends the mission back to the drawing board.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick produced no new empirical findings, yet its most important output was a deliberate act of scientific triage: the swarm recognized that its knowledge graph had grown to 151 disconnected entities with zero hardened causal relations, diluted by off-topic reviews ranging from heart-failure remote monitoring to shoulder-balance prediction. Rather than continue accumulating disconnected facts, the mission executed a hard pivot, concentrating all compute on a single, medically tantalizing question—whether PCSK9, the protein target of widely used cholesterol-lowering drugs, plays a causally distinct role in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) colorectal cancer.

Colorectal cancer is not biologically uniform. MSS tumors typically retain DNA mismatch repair proficiency and often present as immunologically “cold,” whereas MSI tumors are mismatch-repair deficient, hypermutated, and immunologically “hot.” If PCSK9 levels influence cancer risk or viability differently across these subtypes, drugs already approved for cardiovascular disease could, in principle, be repurposed with precision. But correlation is not causation. To test this, the swarm launched a three-pillar orthogonal validation framework. First, cis-pQTL Mendelian randomization—using strict genetic instruments near the PCSK9 gene that alter its blood protein levels (independent variants selected by LD-clumping at r² < 0.001 and robust F-statistics > 10)—to ask whether inherited variation in PCSK9 changes CRC risk differently in MSS and MSI strata across massive genome-wide association datasets. Second, tumor-tissue eQTL colocalization to determine whether the same DNA variant at the 1p34.1–1p32.3 locus drives both PCSK9 expression in actual CRC tumors and overall CRC risk. Third, analysis of DepMap CRISPR knockout screens to test whether PCSK9 loss is differentially essential in mismatch-repair-deficient versus proficient colorectal cancer cell lines, adjusting for mutation burden and genetic lineage.

Because zero new relations were added this tick, the relation count remains at zero; the three updated hypotheses reflect sharpened methodological criteria rather than discovered biological effects. Off-topic entities were permanently archived, clearing the workspace for the mandated triad. While this lack of immediate results may appear to be stasis, it embodies the unglamorous discipline required for credible discovery: ensuring that the next edge entering the graph survives rigorous, multi-modal scrutiny rather than wishful thinking.

The open questions are now razor-sharp. Will the cis-pQTL instruments for PCSK9 survive colocalization with the protein signal and yield directionally consistent Mendelian randomization estimates across at least two independent proteomic studies? If a genetic effect emerges, does the tumor eQTL share a causal variant with CRC risk, with the expression-altering allele matching the MR-predicted risk direction? And will the DepMap essentiality data mirror that same directional story? The swarm will not broaden its search to other therapeutic candidates or disease areas until this specific PCSK9–CRC edge either satisfies all three hardened criteria or fails definitively. We are hopeful that this concentration of force will soon convert hypothesis into evidence.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

The most compelling development this tick was the sharpening of a precise, testable causal question—rather than a premature answer. With 151 scientific entities archived but zero validated causal relations hardened, the swarm focused its entire effort on a single high-priority target: whether the cholesterol-regulating protein PCSK9 exerts a causal influence on colorectal cancer risk, specifically distinguishing between microsatellite-stable (MSS) and microsatellite-instable (MSI) disease subtypes.

PCSK9 is familiar to cardiologists as the target of powerful cholesterol-lowering drugs, yet its role in cancer remains unclear. Colorectal cancers are not uniform; MSI tumors harbor defects in DNA mismatch repair and behave differently from the more common MSS tumors. To rigorously test causality without relying on a single line of evidence, the AI launched three parallel, orthogonal investigations. First, Mendelian randomization treats naturally occurring genetic variants near PCSK9 as natural experiments, asking whether people born with higher genetically predicted PCSK9 protein levels show consistently higher or lower CRC risk across massive biobanks including UK Biobank, FinnGen, and GECCO. Second, tumor-tissue colocalization examines whether the same genetic signals drive PCSK9 expression in actual colorectal tumors and influence overall disease susceptibility. Third, analysis of CRISPR gene-dependency data from cancer cell lines probes whether MMR-deficient cells—mimicking the MSI subtype—rely on PCSK9 differently than MMR-proficient cells.

This tick yielded zero new validated findings, and no causal edge was hardened. Instead, the period was devoted to foundational curation: assembling genome-wide genetic instruments from plasma proteome studies, mapping colorectal tumor expression quantitative trait loci from CPTAC-CRC and TCGA, and structuring the statistical models needed to test for differential PCSK9 essentiality across MMR-defined cell lines. Four hypotheses were refined and updated, tightening the evidentiary thresholds required to declare convergence. In genuine discovery science, such preparatory rigor is not a null result—it is the necessary scaffolding that prevents false positives.

Looking ahead, the mission will execute the three locked validation streams to answer a tightly defined set of questions. Does the genetic evidence for PCSK9 on CRC risk point in the same direction across every independent data source? Do tumor eQTLs and GWAS signals colocalize with high posterior probability, suggesting a shared causal variant? And do CRISPR screens reveal a statistically significant interaction between PCSK9 loss and MMR status? If all three independent signals align, the swarm will have forged its first hardened causal edge; if they diverge, the hypothesis will be appropriately deprioritized. We are hopeful about the clarity this orthogonal design will bring, but we maintain strict scientific humility: no biological conclusion about PCSK9 in colorectal cancer can be drawn until these streams produce convergent, experimentally validated data.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs AI swarm launched a precision investigation into one of oncology’s most intriguing repurposing questions: whether PCSK9—the protein targeted by widely used cholesterol-lowering drugs—plays a causal, subtype-specific role in colorectal cancer. Recognizing that the literature currently offers no hardened causal links between PCSK9 and CRC, the system refused to rely on single-source associations. Instead, it deployed three independent validation modules in parallel, each designed to test the relationship through a different biological lens while explicitly separating microsatellite-stable (MSS) from microsatellite-unstable (MSI) tumors. No definitive empirical findings were produced this tick; rather, the mission laid rigorous methodological groundwork and refined three sharpened hypotheses that will be put to the test in the coming cycle.

Colorectal cancers broadly divide into two biological camps. MSS tumors retain normal DNA mismatch repair machinery, whereas MSI tumors are hypermutated and MMR-deficient. These subtypes respond differently to immunotherapy and may harbor distinct genetic dependencies. PCSK9 has surfaced in cancer research because it can modulate lipid metabolism and tumor microenvironments, but existing claims of causality remain soft. To harden a potential link, the AI is pursuing three independent lines of evidence. First, Mendelian randomization using inherited genetic variants that alter PCSK9 protein levels in blood, drawn from large proteomics studies such as UKB-PPP and INTERVAL. Second, colocalization testing in primary tumor tissue to determine whether the same DNA variants that change PCSK9 gene expression also influence CRC risk. Third, CRISPR knockout screens across cancer cell lines to test whether MMR-deficient cells are uniquely dependent on PCSK9 for survival.

This tick focused on instrument curation and experimental design rather than premature inference. For the genetic analysis, the AI extracted cis-pQTLs—variants near the PCSK9 gene that robustly predict circulating protein levels—and applied strict quality filters, retaining only instruments with strong statistical support for shared genetic signals. For the tumor analysis, it prepared comparisons of PCSK9 expression quantitative trait loci between MSS and MSI subsets in datasets such as CPTAC-CRC and TCGA. For the functional screen, it structured a covariate-adjusted model to compare PCSK9 dependency in MMR-deficient versus MMR-proficient colorectal lines from DepMap. The result was zero premature findings, but a suite of analyses now poised to yield interpretable, directionally consistent signals.

The critical questions now hanging in the balance are whether genetically predicted PCSK9 levels consistently track with MSS or MSI CRC risk across independent proteomic sources; whether tumor eQTL signals at the PCSK9 locus share genetic architecture with CRC risk variants in a subtype-aligned manner; and whether CRISPR knockout of PCSK9 selectively impairs the fitness of MMR-deficient cells. The next tick will execute these statistical tests across all three modules. Should two or more independent lines converge on a coherent, subtype-specific story, the mission will have generated a genetically anchored, experimentally testable candidate for drug repurposing.

We remain cautiously optimistic that this orthogonal strategy—demanding agreement between population genetics, tumor genomics, and functional genomics before any claim is hardened—offers the most direct path to a trustworthy biological signal. The absence of findings today is not an absence of progress; it is the necessary discipline of real science.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs swarm made a disciplined wager: instead of chasing scattered correlations across medicine, it funneled its entire capacity into one precise causal question—whether the cholesterol-regulating protein PCSK9 influences microsatellite-stable (MSS) and microsatellite-unstable (MSI) colorectal cancer through fundamentally different biological mechanisms. The most significant development is not a confirmed finding, but the activation of a rigorous, three-layered validation framework. By demanding that any signal simultaneously survive genetic epidemiology, functional CRISPR genomics, and tumor-regulatory colocalization, the mission is attempting to break its “zero-edge” barrier with a single, hardened causal link rather than a cloud of weak associations.

Colorectal cancers are not uniform. MSI tumors arise from broken DNA mismatch repair machinery and behave differently from MSS tumors in metabolism, immune recognition, and drug response. PCSK9 is famous in cardiology, yet its role in CRC biology remains unclear. To test whether genetically driven variation in PCSK9 protein levels affects one subtype over the other, the swarm executed three parallel streams. First, Mendelian randomization used genetic instruments from large plasma proteomics biobanks to ask whether blood-based PCSK9 variation predicts MSS or MSI risk, requiring that the genetic signals physically overlap with CRC risk loci and replicate across independent sources. Second, CRISPR essentiality screens from hundreds of cancer cell lines were queried to see if knocking out PCSK9 differentially harms MMR-deficient versus MMR-proficient cells. Third, the swarm examined whether those same genetic instruments regulate PCSK9 expression inside actual primary tumors, using data from CPTAC and TCGA stratified by mismatch repair status.

No validated causal relations were confirmed this tick. The knowledge base holds steady at zero edges—a deliberate null that reflects the mission’s refusal to admit underpowered or confounded signals. Three hypotheses were updated as the swarm refined its expectations for effect direction and covariate adjustment, but the stringent thresholds successfully excluded spurious links. This absence of findings is scientifically informative: it indicates that if a PCSK9–CRC subtype relationship exists, it is subtle enough to require the full orthogonal triangulation now underway.

Outstanding questions for the next tick center on convergence. Will the plasma protein genetic signals colocalize with tumor expression quantitative trait loci in a subtype-specific manner? Will the CRISPR knockout data align directionally with the Mendelian randomization estimates? Overall confidence remains cautiously focused on the PCSK9 axis—the biological rationale linking lipid metabolism to mismatch repair status is plausible—but the swarm will not expand to other candidates or therapeutic areas until at least one causal edge survives all three validation gates.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the AI swarm identified its highest-leverage path to break the mission’s “zero-edge barrier”: a focused, three-pronged interrogation of whether PCSK9—the cholesterol-regulating protein already targeted by heart medications—plays a causal, subtype-specific role in colorectal cancer. Rather than forcing a premature finding, the cycle achieved something equally critical at this early stage: it distilled a crowded field of 151 disconnected entities into a rigorous, testable causal framework centered on microsatellite-stable (MSS) versus microsatellite-instable (MSI) tumor biology.

Colorectal cancers are not biologically uniform. MSS tumors possess intact mismatch repair machinery, while MSI tumors accumulate frequent DNA replication errors, carry heavy mutation burdens, and interact with the immune system in fundamentally different ways. PCSK9 has surfaced across fragmented literature as a plausible modulator of tumor behavior, but no hardened causal link to CRC exists. To draw the first credible edge in the knowledge graph, the AI designed three orthogonal tests that must point in the same direction before any relation is accepted. First, Mendelian randomization using genetic instruments from two large plasma proteome studies (UKB-PPP and INTERVAL) asks whether lifelong higher PCSK9 levels causally alter CRC risk by subtype. Second, colocalization mapping in patient tumors (CPTAC-CRC and TCGA) tests whether the DNA variants that control PCSK9 expression in cancer tissue are the same variants that predispose to CRC. Third, differential CRISPR essentiality analysis in cancer cell lines (DepMap) probes whether MSI or MSS tumors are more dependent on PCSK9 for survival, carefully controlling for mutation burden, BRAF/KRAS driver status, and DNA methylation patterns.

No new findings were confirmed this tick—the knowledge base remains at zero relations. However, seven hypotheses were refined, and the system aggressively archived off-target noise—including literature on heart failure remote monitoring, shoulder surgery parameters, and attention biomarkers—to protect the integrity of the PCSK9–CRC axis. This absence of findings reflects intentional methodological discipline rather than failure. By demanding directional consistency across both population proteomic sources, a posterior probability of shared causality above 0.8 for each genetic instrument, and a false-discovery rate below 0.05 in functional screens, the mission ensures that the first edge added to the graph will be robust and reproducible.

What emerges is a clear, falsifiable prediction: if PCSK9 truly influences colorectal cancer risk or progression differently in MSS versus MSI contexts, all three evidence streams should align. The current setup indicates this hypothesis is tractable and warrants immediate execution, but it remains unproven. Next, the AI will run the full statistical gauntlet—proteomic Mendelian randomization, tumor eQTL colocalization, and covariate-adjusted DepMap essentiality—to see whether PCSK9 survives as a subtype-specific causal candidate. Outstanding questions include whether any observed link is mediated by cholesterol-dependent signaling or by direct effects on the tumor microenvironment, and whether the effect directions will be bidirectionally consistent across germline genetics, tumor transcriptomics, and cell-line fitness data.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs swarm placed a high-stakes bet on a single, druggable target: the cholesterol-regulating protein PCSK9. With 151 entities mapped but zero hardened causal edges confirmed so far, the mission is attempting to break through by testing whether PCSK9 exerts a subtype-specific causal influence on colorectal cancer—specifically distinguishing between microsatellite-stable (MSS) and microsatellite-instable (MSI) tumors. Rather than chasing scattered signals, the swarm executed a mandated three-stream orthogonal validation, simultaneously probing genetic, tissue, and functional evidence to meet the strict criteria required to declare its first hardened causal relation.

Colorectal cancers fall into two broad biological camps. MSI tumors harbor broken DNA repair machinery and behave very differently from the more common MSS subtype. If PCSK9 truly drives risk in one but not the other—or pushes them in opposite directions—it could open unexpected avenues for repurposing existing heart medications. To test this, the swarm deployed three complementary approaches: Mendelian randomization, which uses naturally occurring genetic variations as proxies for lifelong PCSK9 levels in large biobanks; tissue colocalization mapping, which asks whether the same genetic variants control PCSK9 expression in primary tumors and influence overall cancer risk; and CRISPR dependency screening, which tests whether MSI and MSS cancer cell lines differ in how desperately they need PCSK9 to survive.

No new empirical findings emerged this tick, yet the cycle was far from empty. The swarm updated three working hypotheses and aggressively pruned off-target entities—from heart failure remote monitoring studies to shoulder surgery parameters—signaling a disciplined refusal to dilute its focus. This methodological austerity suggests the AI is holding itself to a high bar: only convergent evidence across all three independent streams will earn the first edge in the knowledge graph. In exploratory science, such restraint is itself a valuable output, guarding against false positives while the validation machinery runs.

The path forward now depends on whether these three streams converge. Will genetic instruments from UKB-PPP and INTERVAL yield directionally consistent Mendelian randomization estimates across multiple independent genome-wide association studies? Will PCSK9 expression signals in CPTAC-CRC and TCGA tumor tissues colocalize with colorectal cancer risk loci in a subtype-specific manner? And will DepMap CRISPR screens reveal statistically significant differential dependency between MSI and MSS cell lines, with the effect direction matching the genetic predictions? The mission will investigate these questions next, knowing that if all three align, the resulting hardened edge would represent a genuinely causal, actionable insight.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most important insight is a razor-sharp strategic clarification: to break the current zero-evidence barrier in our colorectal cancer knowledge graph, the investigation must zero in on a single, testable nexus—the PCSK9 protein and its potentially divergent role in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) tumors. Faced with 151 disconnected entities and no hardened relations, the AI determined that only an exact orthogonal triad—genetic instrument validation in plasma, tissue signal matching in tumors, and CRISPR dependency testing in cancer cells—can forge the first reliable edge. Three hypotheses were refined to reflect this surgical focus, but no new empirical relation was yet established, a reminder that in early-stage discovery, framing the precise question often precedes the answer.

Colorectal cancers are not uniform. Roughly 15 percent carry defects in their DNA “spell-checker” machinery, known as mismatch repair deficiency, which produces MSI tumors that behave and respond to therapy differently than their MSS counterparts. PCSK9 is best known for regulating cholesterol, yet emerging clues suggest it may also influence tumor biology through inflammation or survival pathways. The core challenge is determining whether genetically driven differences in PCSK9 protein levels truly alter colorectal cancer risk—and whether any such effect is specific to the MSI or MSS subtype rather than a blunt association across all cases.

To interrogate this, the AI designed a tightly scoped three-layer study. First, it identified genetic variants near PCSK9 that change its protein levels in blood, drawn from large proteomics studies (UKB-PPP and INTERVAL), intending to use them as natural experiments in Mendelian randomization. This approach leverages nature’s random assignment of genes to ask whether people born with higher or lower PCSK9 face different MSS or MSI cancer risks. Second, it prepared to test whether those same blood-based genetic signals appear in actual tumor tissue by colocalizing them with gene and protein expression data from CPTAC-CRC and TCGA. Third, it structured a DepMap CRISPR analysis to ask whether mismatch-repair-deficient cancer cells depend on PCSK9 to survive compared with repair-proficient cells.

As of this tick, the analysis has produced zero new empirical findings; the knowledge graph still holds 151 entities and zero hardened relations. The three updated hypotheses reflect refined assumptions about statistical modeling and instrument selection rather than confirmed biological associations. This is the honest texture of real science: the AI has mapped the precise experimental geometry required, but the harmonizations, colocalization posteriors, and dependency regressions remain to be executed. Whether PCSK9 is a causal risk factor, a synthetic-lethal vulnerability, or a neutral bystander in MSI colorectal cancer remains unproven and demands experimental validation.

Next, the mission will run the full colocalization pipeline to see if plasma PCSK9 signals share a causal variant with tumor expression, complete the subtype-stratified Mendelian randomization across both proteomic discovery cohorts, and finalize the DepMap differential-essentiality models conditioned on mismatch repair status. The critical open question is directional alignment: if higher PCSK9 genetically predicts altered MSI risk, do MSI tumor cells simultaneously crave PCSK9 for survival, or can they tolerate its loss? Should all three orthogonal planes converge, they could reveal a subtype-specific therapeutic vulnerability. Until then, these hypotheses remain precisely that—hypotheses.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.